Recombinant Human CD26 Protein
Beta LifeScience
SKU/CAT #: BLPSN-0833
Recombinant Human CD26 Protein
Beta LifeScience
SKU/CAT #: BLPSN-0833
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | N/A |
Host Species | Human |
Accession | NP_001926.2 |
Synonym | ADABP, ADCP2, CD26, DPPIV, TP103 |
Background | Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes. |
Description | The native mature form of human DPPIV (NP_001926.2) extracellular domain (Asn 29-Pro 766) was expressed and purified. |
Source | HEK293 |
Predicted N Terminal | Asn 29 |
AA Sequence | Asn 29-Pro 766 |
Molecular Weight | The recombinant human DPPIV exists as the mature active form, and consists of 738 a.a. with a predicted molecular mass of 85.4 kDa. The apparent molecular mass of the glycosylated rhDPPIV is approximately 95 kDa in SDS-PAGE under reducing conditions. |
Purity | >70% as determined by SDS-PAGE |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
Bioactivity | 1. Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The specific activity is > 2,500 pmoles/min/ug.2. Using the Octet RED System, the affinity constant (Kd) of human DPP4 bound to Spike (HCoV-EMC/2012) was 20 nM.3. Using the Octet RED System, the affinity constant (Kd) of human DPP4 bound to Spike (HCoV-EMC/2012) was 50 nM.4. Using the Octet RED System, the affinity constant (Kd) of human DPP4 bound to Spike (HCoV-EMC/2012) (ECD, aa 1-1297) was 33 nM.5. Using the Octet RED System, the affinity constant (Kd) of human DPP4 bound to Spike-His (aa 1-760) was 12 nM. |
Formulation | Lyophilized from sterile 100mM NaCl, 50mM Tris, pH 7.5. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |